Literature DB >> 12457782

The power of the protocol.

Marissa Lassere1, Kent Johnson.   

Abstract

Mesh:

Year:  2002        PMID: 12457782     DOI: 10.1016/S0140-6736(02)11652-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  11 in total

1.  Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research.

Authors:  An-Wen Chan; Karmela Krleza-Jerić; Isabelle Schmid; Douglas G Altman
Journal:  CMAJ       Date:  2004-09-28       Impact factor: 8.262

2.  Outcome reporting among drug trials registered in ClinicalTrials.gov.

Authors:  Florence T Bourgeois; Srinivas Murthy; Kenneth D Mandl
Journal:  Ann Intern Med       Date:  2010-08-03       Impact factor: 25.391

3.  SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials.

Authors:  An-Wen Chan; Jennifer M Tetzlaff; Peter C Gøtzsche; Douglas G Altman; Howard Mann; Jesse A Berlin; Kay Dickersin; Asbjørn Hróbjartsson; Kenneth F Schulz; Wendy R Parulekar; Karmela Krleza-Jeric; Andreas Laupacis; David Moher
Journal:  BMJ       Date:  2013-01-08

4.  Pediatric versus adult drug trials for conditions with high pediatric disease burden.

Authors:  Florence T Bourgeois; Srinivas Murthy; Catia Pinto; Karen L Olson; John P A Ioannidis; Kenneth D Mandl
Journal:  Pediatrics       Date:  2012-07-23       Impact factor: 7.124

5.  SPIRIT 2013 Statement: defining standard protocol items for clinical trials.

Authors:  An-Wen Chan; Jennifer M Tetzlaff; Douglas G Altman; Andreas Laupacis; Peter C Gøtzsche; Karmela Krle A-Jerić; Asbjørn Hrobjartsson; Howard Mann; Kay Dickersin; Jesse A Berlin; Caroline J Dore; Wendy R Parulekar; William S M Summerskill; Trish Groves; Kenneth F Schulz; Harold C Sox; Frank W Rockhold; Drummond Rennie; David Moher
Journal:  Rev Panam Salud Publica       Date:  2015-12

6.  SPIRIT 2013 statement: defining standard protocol items for clinical trials.

Authors:  An-Wen Chan; Jennifer M Tetzlaff; Douglas G Altman; Andreas Laupacis; Peter C Gøtzsche; Karmela Krleža-Jerić; Asbjørn Hróbjartsson; Howard Mann; Kay Dickersin; Jesse A Berlin; Caroline J Doré; Wendy R Parulekar; William S M Summerskill; Trish Groves; Kenneth F Schulz; Harold C Sox; Frank W Rockhold; Drummond Rennie; David Moher
Journal:  Ann Intern Med       Date:  2013-02-05       Impact factor: 25.391

7.  Review and publication of protocol submissions to Trials - what have we learned in 10 years?

Authors:  Tianjing Li; Isabelle Boutron; Rustam Al-Shahi Salman; Erik Cobo; Ella Flemyng; Jeremy M Grimshaw; Douglas G Altman
Journal:  Trials       Date:  2016-12-16       Impact factor: 2.279

8.  No short-cut in assessing trial quality: a case study.

Authors:  Karim F Hirji
Journal:  Trials       Date:  2009-01-07       Impact factor: 2.279

9.  Bias, spin, and misreporting: time for full access to trial protocols and results.

Authors:  An-Wen Chan
Journal:  PLoS Med       Date:  2008-11-25       Impact factor: 11.069

10.  Promoting public access to clinical trial protocols: challenges and recommendations.

Authors:  An-Wen Chan; Asbjørn Hróbjartsson
Journal:  Trials       Date:  2018-02-17       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.